New England Journal of Medicine

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D

T Tarik Asselah (Université de Paris-Cité, INSERM Unité Mixte de Recherche 1149, Paris) M Michael A. Chattergoon (Vir Biotechnology, San Francisco) A Alina Jucov (Arensia Exploratory Medicine, Düsseldorf, Germany) A Anca Streinu-Cercel (National Institute for Infectious Diseases Matei Balş, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania) P Pietro Lampertico (Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan) H Heiner Wedemeyer P Patrick T. Kennedy (Centre for Immunobiology and Infection, Blizard Institute, Barts and the London School of Medicine and Dentistry, London) E Edward J. Gane (Auckland Clinical Studies, Auckland, New Zealand) B Brianna L. Bullard (Vir Biotechnology, San Francisco) S Sophia Chow (Vir Biotechnology, San Francisco) D Desiree Santos (Vir Biotechnology, San Francisco) G Gregory Camus (Vir Biotechnology, San Francisco) Y Yimeng Lu (Vir Biotechnology, San Francisco) C Cara Pilowa (Vir Biotechnology, San Francisco) C Carey Hwang (Vir Biotechnology, San Francisco) T Todd Correll (Vir Biotechnology, San Francisco) K Kosh Agarwal (Institute of Liver Studies, Kings College Hospital NHS Trust, London)
Download PDF View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 394, Issue 4
Published January 22, 2026
Pages 343-353
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences

Authors (17)

T

Tarik Asselah

Université de Paris-Cité, INSERM Unité Mixte de Recherche 1149, Paris

M

Michael A. Chattergoon

Vir Biotechnology, San Francisco

A

Alina Jucov

Arensia Exploratory Medicine, Düsseldorf, Germany

A

Anca Streinu-Cercel

National Institute for Infectious Diseases Matei Balş, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

P

Pietro Lampertico

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan

H

Heiner Wedemeyer

P

Patrick T. Kennedy

Centre for Immunobiology and Infection, Blizard Institute, Barts and the London School of Medicine and Dentistry, London

E

Edward J. Gane

Auckland Clinical Studies, Auckland, New Zealand

B

Brianna L. Bullard

Vir Biotechnology, San Francisco

S

Sophia Chow

Vir Biotechnology, San Francisco

D

Desiree Santos

Vir Biotechnology, San Francisco

G

Gregory Camus

Vir Biotechnology, San Francisco

Y

Yimeng Lu

Vir Biotechnology, San Francisco

C

Cara Pilowa

Vir Biotechnology, San Francisco

C

Carey Hwang

Vir Biotechnology, San Francisco

T

Todd Correll

Vir Biotechnology, San Francisco

K

Kosh Agarwal

Institute of Liver Studies, Kings College Hospital NHS Trust, London

Related Articles from this Journal

Doctor’s Dirty Little Secret — The Cost of Silence

Tara Khan Aug 2026 10.1056/nejmp2515506

Obstructive Hypertrophic Cardiomyopathy

Julian-Kai Nishizono, Marohito Nakata Aug 2026 10.1056/nejmicm2603868

T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation

Martina Schatzl, Katharina A. Mayer et al. Jul 2026 10.1056/nejmc2603853

Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?

Jerry Avorn Jul 2026 10.1056/nejmp2604841

Precision Intensification in Metastatic Prostate Cancer

Rana R. McKay Jul 2026 10.1056/nejme2605582